European Pharmaceutical Review

FEBRUARY 8, 2023

GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.

Marketing 98

Marketing Sales Physicians Patients 98

PM360

SEPTEMBER 21, 2023

Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

AUGUST 27, 2024

and ramped up sales of PFA systems in Europe. Based on brisk uptake in the latter half of the first quarter, it appeared that PFA would account for at least 30% of the ablation market and $1 billion in sales by the end of 2024. Abbott’s Volt should join the party in early 2026. s Farapulse. Pulse Biosciences Inc.,

Marketing 52

Marketing Competition FDA Electronics 52

Pharmaceutical Technology

JULY 26, 2022

This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market. The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%.

Marketing 122

Marketing Transportation Leads Patients 122

PM360

APRIL 7, 2023

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Given the volume of 340B sales (13% of total U.S.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

Pharmaceutical Technology

JANUARY 10, 2023

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

Marketing 52

Marketing Physicians Leads Sales 52